Background: In the RAPID1 randomized controlled trial (RCT), certolizumab pegol (CZP) every 2 weeks (Q2W) plus MTX over 52 weeks provided rapid improvements in signs and symptoms and inhibition of radiographic damage in patients with active RA. Here we examine the safety and efficacy of CZP plus MTX over 5 years in RA.
Background: Predicting response to anti-TNF alpha inhibitors (TNFi) in RA patients is challenging. Therefore there is a high need for identification of biomarkers of clinical outcome to guide therapeutic decisions. A number of studies suggested that response to TNFi may partly be explained by modulation of synovial ectopic lymphocytic aggregates (ELN) within the synovial tissue. Certolizumab pegol is a pegylated fully humanized TNFi. At present data regarding in vivo effects on pathobiological responses within the synovial membrane of patients with RA are limited. In particular, whether specific synovial pathotypes predict response to treatment is unknown. The aim of this study is to investigate whether the presence of synovial ELN at baseline predicts clinical response to treatment with certolizumab pegol in RA patients. Methods: A cohort of biologic-naïve RA patients who qualified for TNFi according to NICE guidance (National Institute for Health and Clinical Excellence, http://guidance.nice.org.uk/TA186) was recruited at Barts and the London Hospital. Patients underwent ultrasound guided synovial biopsy of an active joint prior to commencing therapy with certolizumab pegol. Following 3 months of therapy, response to treatment was assessed according to EULAR response criteria. Paraffin embedding sequentially cut sections of synovial tissue underwent H&E staining and immunohistochemical staining for CD20 to detect B cells. Sections were graded as either diffuse or aggregate infiltrate as previously described. The study received local ethics approval.
Results: Study population includes 25 RA patients, median age 54 (IQR: 45À59), median disease duration 4 years (IQR: 2-8.5) and median DAS28 6.2 (IQR: 5.7-6.8); 10 patients (40%) had an erosive disease and 17 (68%) were seropositive for RF or anti-citrullinated protein antibodies (anti-CCP). 18 patients (72%) responded to the drug according to EULAR response criteria (32% were good responders and 40% moderate responders). ELN was found in 11 patients (44%). A stepwise logistic regression analysis was performed by entering several baseline variables: gender, age, disease duration, number of previous DMARDs, presence of erosions, RF and anti-CCP status, DAS28, HAQ, presence of ELN. Only presence of ELN was identified as a potential predictor of response (Fisher exact test, P < 0.001). Conclusion: To the authors' knowledge, this is the first time that clinical response to certolizumab pegol has been evaluated in association with synovial ELN. Our work shows that the presence of ELN may be a useful predictor of primary clinical response to certolizumab pegol treatment, in line with previous data observed for other TNFi, suggesting that histopathology could be considered in the future as a potential key tool to guide therapeutic decisions for RA patients. Funding: This study was funded by UCB. The company played no part in the conception, design or execution of the study. Disclosure statement: The authors have declared no conflicts of interest. Background: Cardiovascular (CV) risk is increased among patients with RA and is comparable to that observed for patients with type 2 diabetes, largely driven by the high systemic inflammatory burden associated with RA. The heightened inflammatory state in RA is thought to account for a lipid paradox, in which serum cholesterol is inversely related to inflammation in patients with untreated RA. Suppression of disease activity and inflammation with RA therapies, including tocilizumab (TCZ), has been associated with increases in serum lipid levels in RA patients, and is thought to reflect a normalization of lipid levels to those seen in the general population. To ascertain what impact TCZ may have on cholesterol levels in the absence of inflammation, the impact of therapeutic and supratherapeutic doses of TCZ on cholesterol levels in healthy subjects were examined. Methods: This study was conducted as a single dose, randomized, double-blind, placebo-controlled, parallel group study investigating therapeutic and a supra-therapeutic doses of TCZ. Healthy subjects were randomized 1:1:1 to placebo (PBO), TCZ 10 mg/kg, or TCZ 20 mg/kg, and received a single i.v. dose on Day 1. The dose of 10 mg/ kg, given as a single dose, was selected because this dose mimics the 102 TABLE 1. Summary of change from baseline of cholesterol levels by study treatment average therapeutic TCZ exposure (AUC, C max ) at steady-state of an 8 mg/kg dose given every 4 weeks to an RA patient. Serum levels of total cholesterol (TCh), high-density lipoprotein-cholesterol (HDL) and low-density lipoprotein-cholesterol (LDL) were assessed after a 12-hour fast at baseline (BL), days 1, 2, 3, 4, 5, 8, 11, 15, 22, 29, .
TOCILIZUMB DID NOT SIGNIFICANTLY INCREASE SERUM CHOLESTEROL LEVELS IN HEALTHY SUBJECTS
Results: Administration of a single dose of TCZ resulted in a transient small increase in TCh and LDL, tending to peak around Day 8 for both TCZ groups. The magnitude of these increases in healthy subjects were markedly less than those reported for RA patients treated with TCZ and by Day 50, levels of TCh, HDL, LDL in the 10 mg/kg group had returned to, or were lower than, baseline levels (Table 1) . Mean values for TCh, HDL, and LDL were within the normal range for all groups. Conclusion: There were no meaningful increases in TCh, HDL or LDL in healthy subjects with either a single therapeutic or supra-therapeutic dose of TCZ. This observation is supportive of the notion that the reported elevation of cholesterol levels with TCZ in RA patients is a consequence of suppression of the inflammatory burden and the return of cholesterol levels towards a non-inflammatory state, as found in the general population. 
